3d6b96fa-5efa-4c8a-9a12-2718304252d4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- OXIDATIVE_PHOSPHORYLATION+0.500
- CHOLESTEROL_HOMEOSTASIS+0.460
- P53_PATHWAY+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- MYC_TARGETS_V1+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.360
- FATTY_ACID_METABOLISM+0.350
- GLYCOLYSIS+0.340
- MTORC1_SIGNALING+0.340
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- HEDGEHOG_SIGNALING-0.320
- UV_RESPONSE_DN-0.290
- ALLOGRAFT_REJECTION-0.280
- INTERFERON_ALPHA_RESPONSE-0.220
- INTERFERON_GAMMA_RESPONSE-0.220
- INFLAMMATORY_RESPONSE-0.200
- PANCREAS_BETA_CELLS-0.180
- IL6_JAK_STAT3_SIGNALING-0.170
- SPERMATOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168575 | — | — | 0.871 |
| 2 | 395e165c-8e84-4203-af1e-f7e1f17d2edd | — | — | 0.827 |
| 3 | MNG738 | — | — | 0.824 |
| 4 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.815 |
| 5 | TCGA-ZF-AA5N-01A-11R-A42T-07 | — | — | 0.813 |
| 6 | TCGA-90-7769-01A-11R-2125-07 | — | cohortSQ2 | 0.804 |
| 7 | SRR1516057 | — | — | 0.801 |
| 8 | SRR8392893 | — | cohortSQ2 | 0.797 |
| 9 | SRR1516051 | — | — | 0.797 |
| 10 | TCGA-IQ-7632-01A-11R-2081-07 | — | — | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.460 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.430 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.340 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.290 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.230 | Inavolisib | — uncovered |